Compounds > 5-amino-6-ribitylamino-2,4-(1h,3h)pyrimidinedione
Page last updated: 2024-11-08

5-amino-6-ribitylamino-2,4-(1h,3h)pyrimidinedione

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-amino-6-ribitylamino-2,4-(1H,3H)pyrimidinedione: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

5-amino-6-(D-ribitylamino)uracil : An aminouracil that is D-ribitol in which the hydroxy group at position 1 is substituted by the 6-amino group of 5,6-diaminouracil. Early intermediate in bacterial riboflavin synthesis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID193516
CHEBI ID15934
SCHEMBL ID1921542
MeSH IDM0120641

Synonyms (35)

Synonym
5-arpd
5-a-ru
5-amino-6-ribitylaminouracil
5-amino-2,6-dioxo-4-ribitylaminopyrimidine
5-amino-6-ribitylamino-2,4-(1h,3h)pyrimidinedione
17014-74-3
1-[(5-amino-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)amino]-1-deoxy-d-ribitol
CHEBI:15934
C04732 ,
5-amino-6-ribitylamino-2,4(1h,3h)-pyrimidinedione
5-amino-6-(1-d-ribitylamino)pyrimidine-2,4(1h,3h)-dione
6-(1-d-ribitylamino)-5-aminouracil
6-(1-d-ribitylamino)-5-amino-2,4-dihydroxypyrimidine
5-amino-6-(1-d-ribitylamino)uracil
4-(1-d-ribitylamino)-5-amino-2,6-dihydroxypyrimidine
5-amino-6-(d-ribitylamino)uracil
5-amino-6-(2,3,4,5-tetrahydroxypentylamino)-1h-pyrimidine-2,4-dione
5-amino-6-[[(2s,3s,4r)-2,3,4,5-tetrahydroxypentyl]amino]-1h-pyrimidine-2,4-dione
d-ribitol, 1-((5-amino-1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)amino)-1-deoxy-
a-4-rap
SCHEMBL1921542
5-amino-6-ribitylamino uracil
1-[(5-amino-2,6-dihydroxypyrimidin-4-yl)amino]-1-deoxy-d-ribitol
4-(1-d-ribitylamino)-5-aminouracil
4-(1-d-ribitylamino)-5-amino-2,6 dihydroxypyrimidine
6-ribitylamino-5-aminouracil
XKQZIXVJVUPORE-RPDRRWSUSA-N
HY-129364A
CS-0105045
DTXSID60937742
1-[(5-amino-2,6-dihydroxypyrimidin-4-yl)amino]-1-deoxypentitol
Q27098306
5-amino-6-(((2s,3s,4r)-2,3,4,5-tetrahydroxypentyl)amino)pyrimidine-2,4(1h,3h)-dione
PD047185
AKOS040732327
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
aminouracil
hydroxypyrimidine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (6)

PathwayProteinsCompounds
flavin biosynthesis I (bacteria and plants)521
toxoflavin biosynthesis318
flavin biosynthesis I (bacteria and plants)1726
flavin biosynthesis II (archaea)828
flavin biosynthesis III (fungi)823
factor 420 biosynthesis522
Flavin biosynthesis221

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (33.33)18.7374
1990's3 (50.00)18.2507
2000's0 (0.00)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.38 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
4-hydroxyphenylpyruvic acid
4-hydroxyphenylpyruvic acid: RN given refers to parent cpd. 4-hydroxyphenylpyruvic acid : A 2-oxo monocarboxylic acid that is pyruvic acid in which one of the methyl hydrogens is substituted by a 4-hydroxyphenyl group.		1.98102-oxo monocarboxylic acid;
phenols		human metabolite
pteridines
[no description available]		2.6830azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
pteridines
uridine
[no description available]		3.2360uridinesdrug metabolite;
fundamental metabolite;
human metabolite
tyrosine
Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.		1.9810amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine		EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
lumazine
lumazine: structure. 2,4-dihydroxypteridine : Any dihydroxypteridine in which the two hydroxy substituents are located at positions 2 and 4.. lumazine : A 2,4-dihydroxypteridine.		1.98102,4-dihydroxypteridine
6,7-dimethyl-8-ribityllumazine, (d)-isomer
6,7-dimethyl-8-ribityllumazine: RN given refers to unlabeled cpd without isomeric designation; structure. 6,7-dimethyl-8-(1-D-ribityl)lumazine : The pteridine that is lumazine substituted with methyl groups at C-6 and -7 and with a 1-D-ribityl group on N-8.		2.0510pteridinescofactor;
Escherichia coli metabolite
ribulose 5-phosphate
ribulose 5-phosphate: RN given refers to cpd without isomeric designation. D-ribulose 5-phosphate : The D-enantiomer of ribulose 5-phosphate that is one of the end-products of the pentose phosphate pathway.. ribulose 5-phosphate : A ribulose phosphate in which the phosphate group is attached at position 5.		1.9610ribulose 5-phosphatemouse metabolite
riboflavin
vitamin B2 : Any member of a group of vitamers that belong to the chemical structural class called flavins that exhibit biological activity against vitamin B2 deficiency. Symptoms associated with vitamin B2 deficiency include glossitis, seborrhea, angular stomaitis, cheilosis and photophobia. The vitamers include riboflavin and its phosphate derivatives (and includes their salt, ionised and hydrate forms).		3.2360flavin;
vitamin B2		anti-inflammatory agent;
antioxidant;
cofactor;
Escherichia coli metabolite;
food colouring;
fundamental metabolite;
human urinary metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite
5-deazaflavin
[no description available]		1.9810pyridopyrimidine
ConditionIndicatedRelationship StrengthStudiesTrials